Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Nat Med. 2010 Sep 12;16(10):1128–1133. doi: 10.1038/nm.2201

Figure 6.

Figure 6

Reversal of Man51-BSA-mediated tolerance in SIGNR1- and IL-10-deficient mice. Analysis of (a) IL-10 and (b) IFN-γ in splenic CD4+ T cells from wild-type (WT) or SIGNR1-deficient (SIGNR1KO) mice receiving oral administration of BSA or Man51-BSA (Man) and stimulated. *p < 0.05. (c) Symptom scores and (d) plasma histamine levels in sensitized and challenged wild-type and SIGNR1-deficient mice. *p<0.05. 6–8 mice per group. (e) Symptom scores and (f) plasma histamine levels in BSA- or Man51-BSA (Man)-treated C3H/hej mice receiving IL-10R-specific or isotype control (Ig Ctr) antibodies as indicated. *p < 0.05. 4–6 mice per group. Antigen-induced (g) symptom scores and (h) specific IgG1 response in mice (wild-type) receiving adoptive transfer of splenic CD4+ T cells from BSA- or Man51-BSA (Man)-treated IL-10-deficient (IL10KO) or wild-type (WT) mice. *p < 0.05. 4–6 mice per group.